Alexandre Lenormand
Chief Executive Officer, co-founder
Engineer, Arts et Métiers ParisTech. Founder of the holding company Schumy Invest, which runs several companies formulating and manufacturing nicotine liquids.
French MedTech · Founded in 2020
DAL LAB is developing the VPM (Medical Personal Vaporiser): a platform for delivering active substances through the lungs in a controlled, reproducible and medically supervised way.
The medical need
Smoking remains the leading cause of preventable death in France. While more than half of daily smokers want to quit, only a minority of attempts lead to lasting abstinence3.
The literature describes two limitations of current aids: nicotine replacement products that are sometimes under-dosed for highly dependent smokers4, and a gestural and behavioural dimension of dependence that is rarely addressed5.
DAL LAB's programme is designed to meet this need.
Our programme
A patented technology designed to deliver a controlled dose, without combustion or propellant gas. The VPM is intended for chronic, ambulatory use, with a target cost of around €0.03 per dose to remain affordable.
A liquid cartridge containing the active substance, with a calculated and calibrated number of doses. Each active substance is subject to a marketing authorisation held by DAL LAB.
A reusable device, targeting CE marking as a Class IIa medical device, with DAL LAB as legal manufacturer.
Controlled nicotine delivery that preserves the hand-to-mouth gesture, within a medical framework. The first building block of a platform that can be extended to other inhaled active substances.
Product under development, not available for sale. The information above describes the programme's objectives and does not constitute efficacy claims.
The smoking cessation market
Investor relations
Having raised €4.8M since 2020, DAL LAB is opening a new round to complete clinical trials, finalise the regulatory work and obtain marketing authorisation.
Business model: DAL LAB develops and certifies the VPM platform, then grants exclusive licences by territory (upfront fees, royalties on sales, supply agreements).
Leadership team
Chief Executive Officer, co-founder
Engineer, Arts et Métiers ParisTech. Founder of the holding company Schumy Invest, which runs several companies formulating and manufacturing nicotine liquids.
Chief Operating Officer, co-founder
COO of Extrapure, a French manufacturer of nicotine bases, and co-founder of Kyado. Business education at EPHEC (Brussels).
Chief Technology Officer, co-founder
Specialist in compliance and certification of nicotine products. Co-founder of the Neopro laboratory, active in the sector since 2013.
Head of Quality Assurance and Regulatory Affairs (QARA)
Degree in pharmacology. Leads quality assurance and regulatory strategy for the VPM (CE marking and marketing authorisation).
Yves Tillet
PharmD, MSc, MBA, FTOPRA. Expert in regulation and assessment of health products
Prof. Daniel Marzin
Toxicology expert, former expert for the French medicines agency (ANSM)
Prof. Philippe Maincent
Expert in pharmaceutical formulation
David Enfrun
ENSAM engineer, expert in medical devices and industrialisation
Jean-Michel Cardot
PharmD, PhD. Expert in biopharmaceutical development
Djakaridia Kouyaté
PhD in chemistry, expert in physical chemistry and analytical methods
Dr Pierre Rouzaud
Physician and toxicologist specialising in tobacco cessation and addiction withdrawal. President of Tabac et Liberté
Dr Marion Adler
Physician specialising in tobacco cessation
Development partners
A project to bring industry back to a 3,000 m² site in Vernouillet (Eure-et-Loir, France), targeting 120 to 150 jobs by 2033, as part of the national Action Cœur de Ville 2 programme and supported by the City of Vernouillet, Agglo du Pays de Dreux and French government services.
Agglo du Pays de Dreux
Supporting DAL LAB's industrial site project in Vernouillet.
Dev'up Centre-Val de Loire
Economic development agency of the Centre-Val de Loire region.
Polepharma
Cluster of the French pharmaceutical manufacturing industry.
France Biotech
Association of French HealthTech entrepreneurs.
Publisher: Dal Lab SAS, a French simplified joint-stock company (société par actions simplifiée) with share capital of €[current capital], registered with the Bobigny Trade and Companies Register under no. 881 728 414. EU VAT no.: FR07881728414. Registered office: 50, rue Bernard, 93000 Bobigny, France. Phone: +33 7 67 81 88 69. Email: contact@dal-lab.tech.
Publishing director: Alexandre Lenormand, President.
Hosting provider: OVH SAS, 2 rue Kellermann, 59100 Roubaix, France. Phone: 1007 (from France).
Intellectual property: all content on this website (text, photographs, visuals, DAL LAB logo) is the property of Dal Lab SAS. Partner logos and trademarks remain the property of their respective owners. Any reproduction without prior authorisation is prohibited.
The VPM is a combination product (medicine and medical device) under development. It does not currently hold a marketing authorisation or CE marking and is not available for sale in any country.
The information on this website presents the company and its research and development programme to investors, partners and professionals. It does not constitute advertising for a medicine or a medical device under the French Public Health Code (articles L.5122-1 and L.5213-1), nor any claim of efficacy or safety, nor medical advice.
If you have questions about quitting smoking, please talk to a healthcare professional or contact your national stop-smoking service (in France: Tabac Info Service, 39 89).
Information about the funding round is provided for information purposes only and does not constitute a public offer of securities or a solicitation to invest. Investing in an unlisted early-stage company carries a risk of partial or total loss of capital, illiquidity and dilution. Any investment decision should be based on a review of the documentation provided by the company and, where appropriate, on independent advice.
Data controller: Dal Lab SAS, 50, rue Bernard, 93000 Bobigny, France. Contact: contact@dal-lab.tech.
Data collected: through the investor pack form: first name, last name, email address and investor profile; through the newsletter sign-up: email address; by email: the information you send us. No health data is collected on this website.
Purposes and legal bases: responding to your requests and sending you the investor pack (Dal Lab's legitimate interest in responding to requests received); managing relations with investors and partners (legitimate interest); sending the newsletter (consent, which you may withdraw at any time).
Recipients: only authorised Dal Lab staff and its technical service providers acting on its behalf (website hosting). Your data is never sold or transferred. It is hosted in the European Union.
Retention period: 3 years from your last contact with Dal Lab; for the newsletter, until you unsubscribe.
Your rights: you have the right to access, rectify, erase, restrict, object to and port your data, to withdraw your consent, and to give instructions on what happens to your data after your death. To exercise these rights, email contact@dal-lab.tech. You may also lodge a complaint with the French data protection authority, the CNIL (www.cnil.fr).
Cookies: non-essential cookies (in particular audience measurement) are only set with your consent, collected through the cookie banner. You can change your choice at any time; it is kept for a maximum of 6 months.
